These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 19541352)

  • 21. One century of allergen-specific immunotherapy for respiratory allergy.
    Incorvaia C; Frati F
    Immunotherapy; 2011 May; 3(5):629-35. PubMed ID: 21554092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Subcutaneous allergen-specific immunotherapy in patients with asthma and allergic rhinitis. 21st century].
    Martín JP
    Rev Alerg Mex; 2009; 56(2):27-9. PubMed ID: 19526950
    [No Abstract]   [Full Text] [Related]  

  • 23. [Sublingual immunotherapy (SLIT) in the allergologist's practice].
    Mösges R; Köberlein J; Keppler J
    MMW Fortschr Med; 2008 Jun; 150 Suppl 2():79-84. PubMed ID: 18712127
    [No Abstract]   [Full Text] [Related]  

  • 24. Recent advances in specific immunotherapy for allergic rhinitis.
    Bousquet J; Hejjaoui A; Michel FB
    Clin Exp Allergy; 1991 Jan; 21 Suppl 1():259-61. PubMed ID: 2032157
    [No Abstract]   [Full Text] [Related]  

  • 25. [Instead of hyposensitization by injection. Dissolving immunotherapy under the tongue?].
    Klein F
    MMW Fortschr Med; 2007 Jan; 149(3):16. PubMed ID: 17632861
    [No Abstract]   [Full Text] [Related]  

  • 26. [New administration routes for immunotherapy].
    Martorell Aragonés A
    Allergol Immunopathol (Madr); 2000; 28(3):93-102. PubMed ID: 10867377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Allergic march in children, from rhinitis to asthma: management, indication of immunotherapy].
    Scheinmann P; Pham Thi N; Karila C; de Blic J
    Arch Pediatr; 2012 Mar; 19(3):330-4. PubMed ID: 22306361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma.
    Rossi RE; Monasterolo G
    Int J Immunopathol Pharmacol; 2005; 18(2):277-85. PubMed ID: 15888250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sublingual immunotherapy and regulatory T cells.
    Ciprandi G; Fenoglio D; Cirillo I; Milanese M; Minuti P
    Allergy; 2006 Apr; 61(4):511-3. PubMed ID: 16512819
    [No Abstract]   [Full Text] [Related]  

  • 30. Sublingual immunotherapy: where do we stand? Present and future.
    Passalacqua G; Pawankar R; Baena-Cagnani CE; Canonica GW
    Curr Opin Allergy Clin Immunol; 2009 Feb; 9(1):1-3. PubMed ID: 19106697
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase.
    Giordano T; Quarta C; Bruno ME; Falagiani P; Riva G
    Eur Ann Allergy Clin Immunol; 2006 Nov; 38(9):310-2. PubMed ID: 17191751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and tolerability of ultra-Rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma.
    Gammeri E; Arena A; D'Anneo R; La Grutta S
    Allergol Immunopathol (Madr); 2005; 33(3):142-4. PubMed ID: 15946626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Allergen-specific immunotherapy].
    Hansen TK; Svendsen UG
    Ugeskr Laeger; 2005 Feb; 167(6):666-71. PubMed ID: 15771384
    [No Abstract]   [Full Text] [Related]  

  • 34. Allergic rhinitis. Outcomes of immunotherapy on symptom control.
    Cook PR
    Otolaryngol Clin North Am; 1998 Feb; 31(1):129-40. PubMed ID: 9530682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma.
    Gammeri E; Arena A; D'Anneo R; La Grutta S
    Allergol Immunopathol (Madr); 2005; 33(4):221-3. PubMed ID: 16045861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anaphylaxis caused by allergen sublingual immunotherapy?
    André C; Fadel R
    Allergy; 2007 Oct; 62(10):1220-1. PubMed ID: 17845597
    [No Abstract]   [Full Text] [Related]  

  • 37. Subcutaneous specific immunotherapy for seasonal allergic rhinitis: a review of treatment practices in the US and Europe.
    Cox L; Calderon MA
    Curr Med Res Opin; 2010 Dec; 26(12):2723-33. PubMed ID: 20979432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sublingual immunotherapy in the treatment of adult allergic rhinitis patients.
    Canonica GW; Passalacqua G
    Allergy; 2006; 61 Suppl 81():20-3. PubMed ID: 16792602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children's real life.
    De Castro G; Zicari AM; Indinnimeo L; Tancredi G; di Coste A; Occasi F; Castagna G; Giancane G; Duse M
    Eur Rev Med Pharmacol Sci; 2013 Aug; 17(16):2225-31. PubMed ID: 23893190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis.
    Dahl R; Kapp A; Colombo G; de Monchy JG; Rak S; Emminger W; Rivas MF; Ribel M; Durham SR
    J Allergy Clin Immunol; 2006 Aug; 118(2):434-40. PubMed ID: 16890769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.